title: Extraordinary antigenicity of the human Ro52 autoantigen.
abstract: Autoantibody levels to the SSA complex, composed of Ro52 and Ro60 proteins, are commonly measured in the diagnoses of Sjögren's Syndrome (SjS), as well as other rheumatological diseases. One of these proteins, Ro52, is an interferon-inducible member of the tripartite motif family bearing a RING motif functioning as an E3 ligase that ubiquitinates interferon regulatory factor 8 and other proteins. Using Luciferase Immunoprecipitation Systems (LIPS) we explored the antigenicity of Ro52 in detail. Analysis of antibody responses against Ro52 and 20 other established antigens revealed that Ro52 had the highest antibody titers and most likely represents one of the most immunogenic human proteins. While the antibody titers in many of the SjS patients were significantly and substantially higher than the controls, all healthy individuals had anti-Ro52 autoantibodies. N- and C-terminal fragments of Ro52 showed immunoreactivity in these serum samples, but the sums of these antibody titers were significantly lower than the antibody titers directed against the full-length Ro52. Antibody profiling of controls and SjS patients with three different N-terminal fragments of Ro52 revealed that the coiled-coil region was the most useful diagnostic (66% sensitivity), followed by the B-box (31% sensitivity), and then the RING-finger (24% sensitivity). The C-terminal region of Ro52, containing the B30.2 domain, showed higher antibody titers in SjS patients compared to controls and this region was responsible for the high level of Ro52 immunoreactivity in healthy individuals. Analysis of immunoreactivity to TRIM5, a Ro52-related protein, and the B30.2 domain from BTN1 and pyrin, failed to show significant antibody titers with the control or SjS patient serum. These results highlight the unusually high level of Ro52 antigenicity and demonstrate that autoantibodies are directed at both linear and conformational epitopes spanning the entire molecule.
authors.forename: Peter D
authors.initials: PD
authors.lastname: Burbelo
authors.forename: Kathryn H
authors.initials: KH
authors.lastname: Ching
authors.forename: Brian L
authors.initials: BL
authors.lastname: Han
authors.forename: Emily R
authors.initials: ER
authors.lastname: Bush
authors.forename: Westley H
authors.initials: WH
authors.lastname: Reeves
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Iadarola
references.citation: Clin Exp Immunol. 1993 Nov;94(2):227-35
references.pmid: 7693382
references.citation: PLoS Negl Trop Dis. 2009;3(5):e438
references.pmid: 19436728
references.citation: Diabetes Care. 2008 Sep;31(9):1824-6
references.pmid: 18535195
references.citation: BMC Biotechnol. 2005 Aug 18;5:22
references.pmid: 16109166
references.citation: Eur J Immunol. 2008 Mar;38(3):619-30
references.pmid: 18286572
references.citation: J Biol Chem. 2009 Aug 14;284(33):22444-22456
references.pmid: 19531472
references.citation: Autoimmun Rev. 2009 Jun;8(7):632-7
references.pmid: 19393201
references.citation: J Immunol. 2006 May 15;176(10):6277-85
references.pmid: 16670339
references.citation: Autoimmunity. 2009 Sep;42(6):515-24
references.pmid: 19657778
references.citation: Retrovirology. 2008 Oct 20;5:96
references.pmid: 18937847
references.citation: J Vis Exp. 2009 Oct 07;(32):
references.pmid: 19812534
references.citation: J Clin Microbiol. 2008 Jul;46(7):2298-304
references.pmid: 18508942
references.citation: Clin Vaccine Immunol. 2009 Mar;16(3):366-71
references.pmid: 19129469
references.citation: Scand J Immunol. 2005 Feb;61(2):109-18
references.pmid: 15683447
references.citation: Clin Immunol. 2007 Nov;125(2):120-6
references.pmid: 17904423
references.citation: Virol J. 2009 May 01;6:45
references.pmid: 19409090
references.citation: Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6200-5
references.pmid: 17400754
references.citation: J Immunol. 2007 Jul 1;179(1):26-30
references.pmid: 17579016
references.citation: Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9982-7
references.pmid: 16785446
references.citation: J Biol Chem. 2005 Sep 30;280(39):33250-61
references.pmid: 15964842
references.citation: Scand J Immunol. 1999 Jun;49(6):620-8
references.pmid: 10354373
references.citation: Diabetes Care. 2010 Apr;33(4):754-6
references.pmid: 20086252
references.citation: Mol Cell Biol. 2006 Aug;26(16):5994-6004
references.pmid: 16880511
references.citation: J Immunol. 2008 Aug 1;181(3):1780-6
references.pmid: 18641315
references.citation: J Clin Immunol. 2008 May;28(3):220-31
references.pmid: 18071879
references.citation: Mol Immunol. 2006 Feb;43(6):588-98
references.pmid: 15916807
references.citation: Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6045-50
references.pmid: 18420815
references.citation: Nat Med. 2005 Jan;11(1):85-9
references.pmid: 15619631
references.citation: Mol Immunol. 2007 Mar;44(9):2406-14
references.pmid: 17118455
references.citation: Lancet. 2005 Jul 23-29;366(9482):321-31
references.pmid: 16039337
references.citation: Biochem Biophys Res Commun. 2006 Jan 6;339(1):415-21
references.pmid: 16297862
references.citation: Virology. 2009 Sep 1;391(2):249-56
references.pmid: 19584018
references.citation: Immunol Today. 1999 May;20(5):234-40
references.pmid: 10322303
references.citation: Immunology. 2002 Jun;106(2):246-56
references.pmid: 12047754
references.citation: Mol Immunol. 2000 Aug;37(10):591-602
references.pmid: 11163395
references.citation: Mol Immunol. 2008 Apr;45(7):2045-54
references.pmid: 18022694
references.citation: Br J Rheumatol. 1993 Jun;32(6):449-55
references.pmid: 8508279
references.citation: J Clin Invest. 1975 May;55(5):1067-73
references.pmid: 804494
references.citation: J Transl Med. 2009 Sep 24;7:83
references.pmid: 19778440
references.citation: Ann Rheum Dis. 2002 Jun;61(6):554-8
references.pmid: 12006334
references.citation: EMBO J. 2001 May 1;20(9):2140-51
references.pmid: 11331580
references.citation: Biochem Biophys Res Commun. 2007 Jan 26;352(4):889-95
references.pmid: 17157815